Since normo-fractionated protocols are the standard of care in radiation oncology, and are discussed to impact on the immune phenotype of HNSCC cells19, we focused on testing the combination of ATM and ATR inhibitors with a 2 × 2 Gy RT setting. This evidence concerns the gene ATM and head and neck squamous cell carcinoma.